Resultados de la búsqueda 51-60 of 3241 for pharmacogenetics
This randomized, active controlled, multicenter Phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with critozinib ...
Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in ...
Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...
Rochester, Minn. The purpose of this study is to explore how using different terms (with or without the word cancer) to identify papillary thyroid cancer might ...
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
Many of the current imaging tests we have for prostate cancer are problematic in their ability to distinguish cancerous from non-cancerous prostate tissue. This ...
Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...
To use Surface-Enhanced Raman Spectroscopy (SERS), a powerful analytical technique that provides detailed and specific information at a molecular level, to ...
Scottsdale/Phoenix, Ariz., Rochester, Minn. This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor ...
Potentially Resectable Pancreatic Cancer - No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (SMA) and, if present, ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?